Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

The user has been using a hair loss treatment regimen including RU58841, minoxidil, and dutasteride, but still experiences hairline recession and fatigue despite high testosterone levels. They are considering adjusting their dutasteride dosage due to concerns about libido and energy levels.

JXL069, also known as PP405, did not lead to hair regrowth after a year of testing. The lack of results may be due to formulation issues, leading to a final attempt with an improved vehicle.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

The conversation discusses recommendations for using topical melatonin for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

The conversation discusses the anticipated release of GT20029, with some users expressing skepticism about its availability. It also mentions the use of treatments like Minoxidil, finasteride, RU58841, and dutasteride for hair loss.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

A user in England seeks advice on where to get a custom blood test for DHT, PRL, estradiol, SHBG, testosterone, and free testosterone before starting dutasteride. They want a baseline measurement before beginning treatment.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

Kintor is potentially pursuing a new hair loss treatment, KT-215, while users express skepticism about the speed and reliability of new product releases. There is a general sentiment that Chinese companies might be more promising in delivering timely solutions.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

The conversation humorously discusses various unconventional and satirical hair loss treatments, including Minoxidil, RU58841, dutasteride, and microneedling. It also mentions bizarre suggestions like topical sharpie, spray paint, and Nutella.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

The conversation is about finding a reliable source for RU58841 in middle Europe, as the user had issues with previous suppliers. Anageninc is suggested as a potential source.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

Poor sleep quality may affect hair growth cycles by disrupting the body's natural clock and stress hormones. The focus should be on improving sleep to support overall health, including hair growth, rather than relying solely on treatments like Minoxidil, finasteride, or RU58841.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.